isoxazoles has been researched along with Small Cell Lung Carcinoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lei, Y; Song, Y; Sun, Y; Tang, R; Yang, K | 1 |
| Aladjem, MI; Beck, E; Ceribelli, M; Chen, L; Dahmen, H; Desai, P; Elenbaas, B; Figg, WD; Itkin, Z; Khan, J; Kim, S; Kindrick, JD; Klumpp-Thomas, C; Lee, MJ; Lee, S; McKnight, C; Michael, S; Nichols, S; Peer, CJ; Pommier, Y; Puc, J; Rajapakse, VN; Redon, CE; Schultz, CW; Sciuto, L; Shimellis, H; Steinberg, SM; Sun, Y; Takahashi, N; Thomas, A; Thomas, CJ; Travers, J; Trepel, JB; Varonin, J; Wei, JS; Wilson, KM; Yuno, A; Zenke, FT; Zhang, X; Zhang, Y; Zimmermann, A | 1 |
| Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A | 1 |
| Choi, J; Jeon, H; Kim, SW; Koh, GY; Lee, DH; Lee, MH; Park, I; Park, KS; Seo, S; Yang, H | 1 |
| Beleggia, F; Büttner, R; Doerr, F; George, J; Hermann, S; Persigehl, T; Rehkämper, T; Reinhardt, HC; Schmitt, A; Thomas, RK; Walter, V; Weber, JP; Wittersheim, M | 1 |
| Aben, N; Avelar, AT; Berns, A; Cozijnsen, M; de Vries, H; Nagel, R; Proost, N; van de Ven, M; van der Vliet, J; Wessels, LFA | 1 |
6 other study(ies) available for isoxazoles and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class II; Humans; Isoxazoles; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Signal Transduction; Small Cell Lung Carcinoma; Survival Analysis; Survival Rate; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2020 |
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Topics: Aged; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Replication; DNA Topoisomerases, Type I; Genomic Instability; Humans; Isoxazoles; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Small Cell Lung Carcinoma | 2021 |
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Resorcinols; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |
Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzodiazepinones; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazines; Pyrazoles; RNA, Messenger; Signal Transduction; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2017 |
Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Survival; Checkpoint Kinase 1; Cisplatin; CRISPR-Associated Protein 9; DNA Damage; Drug Synergism; Etoposide; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Small Cell Lung Carcinoma; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |